Results 231 to 240 of about 69,107 (331)

DPP4 in diabetes [PDF]

, 2015
Diana Röhrborn
core   +1 more source

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]

Cureus
Fukata M, Omura T, Maeda K, Mori T, Kato H, Kuzuya M.   +5 more
europepmc   +1 more source

Triple Drug Fixed Dose Combination Of Sodium-Glucose Co-transporter 2 Inhibitor, Dipeptidyl Peptidase-4 Inhibitor And Metformin In Type 2 Diabetes In India: A Systematic Review With Meta-Analysis [PDF]

Samit Ghosal, Awadhesh Kumar Singh, Ashok Kumar Das   +2 more
openalex   +1 more source

The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health [PDF]

, 2018
Marta Olivares, Valentina Schüppel, Ahmed M. Hassan, Martín Beaumont, Audrey M. Neyrinck, Laure B. Bindels, Alfonso Benítez‐Páez, Yolanda Sanz, Dirk Haller, Peter Holzer, Nathalie M. Delzenne   +10 more
openalex   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

AB1166 The association of the early onset of remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome with dipeptidyl peptidase-4 (DPP4) inhibitor [PDF]

, 2018
Yuji Yoshioka, Masato Mitsuhashi, Amami Kato, Daisuke Kanai, Arnold J. Suda, S. Nagaoka   +5 more
openalex   +1 more source

Association of urinary dipeptidyl peptidase 4 activity with clinical outcomes in people with chronic kidney disease. [PDF]

Sci Rep
Benetti A, Ribeiro-Silva JC, Gómez LM, Tavares CAM, Bensenor IJ, Lotufo PA, Titan SMO, Girardi ACC.   +7 more
europepmc   +1 more source

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley, Christopher T. Rentsch, Elizabeth Williamson, Anoop S. V. Shah, Patrick Bidulka, Charlotte Warren‐Gash, Marleen Bokern, Rohini Mathur   +7 more
wiley   +1 more source

Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]

Cureus
Prakash V, Goel N.
europepmc   +1 more source